Pursuing novel therapeutics targeting NASH/MASH

Madrigal is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction associated steatohepatitis (MASH). Our first therapy was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults with NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) and is being studied in a Phase 3 trial for the treatment of NASH with compensated cirrhosis.

NEWS

More news coming soon.


PRESS RELEASES  >

EVENTS

More events are coming soon.

EVENTS & PRESENTATIONS  >

Madrigal’s ambitious research programs led to the first FDA-approved treatment for NASH.